The influence of ESR1 rs9340799 and ESR2 rs1256049 polymorphisms on prostate cancer risk

详细信息    查看全文

• 作者：Chenying Fu ; Wen-Qi Dong ; Ani Wang ; Guozhen Qiu
• 关键词：ESR ; rs9340799 ; rs1256049 ; Polymorphism ; Prostate cancer ; Meta ; analysis
• 刊名：Tumor Biology
• 出版年：2014
• 出版时间：August 2014
• 年：2014
• 卷：35
• 期：8
• 页码：8319-8328
• 全文大小：1,366 KB
• 参考文献：1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-0. CrossRef
  2. Becker N. Epidemiology of prostate cancer. Radiologe. 2011;51:922-. CrossRef
  3. McDougall JA, Li CI. Trends in distant-stage breast, colorectal, and prostate cancer incidence rates from 1992 to 2004: potential influences of screening and hormonal factors. Horm Cancer. 2010;1:55-2. CrossRef
  4. Harkonen PL, Makela SI. Role of estrogens in development of prostate cancer. J Steroid Biochem Mol Biol. 2004;92:297-05. CrossRef
  5. Ellem SJ, Risbridger GP. The dual, opposing roles of estrogen in the prostate. Ann N Y Acad Sci. 2009;1155:174-6. CrossRef
  6. Menasce LP, White GR, Harrison CJ, Boyle JM. Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique. Genomics. 1993;17:263-. CrossRef
  7. Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, et al. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab. 1997;82:4258-5.
  8. Herrington DM, Howard TD, Brosnihan KB, McDonnell DP, Li X, Hawkins GA, et al. Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation. 2002;105:1879-2. CrossRef
  9. Maguire P, Margolin S, Skoglund J, Sun XF, Gustafsson JA, Borresen-Dale AL, et al. Estrogen receptor beta (ESR2) polymorphisms in familial and sporadic breast cancer. Breast Cancer Res Treat. 2005;94:145-2. CrossRef
  10. Beuten J, Gelfond JA, Franke JL, Weldon KS, Crandall AC, Johnson-Pais TL, et al. Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:1869-0. CrossRef
  11. Sissung TM, Danesi R, Kirkland CT, Baum CE, Ockers SB, Stein EV, et al. Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy. J Clin Endocrinol Metab. 2011;96:E368-2. CrossRef
  12. Balistreri CR, Caruso C, Carruba G, Miceli V, Candore G. Genotyping of sex hormone-related pathways in benign and malignant human prostate tissues: data of a preliminary study. OMICS. 2011;15:369-4. CrossRef
  13. Szendroi A, Speer G, Tabak A, Kosa JP, Nyirady P, Majoros A, et al. The role of vitamin D, estrogen, calcium sensing receptor genotypes and serum calcium in the pathogenesis of prostate cancer. Can J Urol. 2011;18:5710-.
  14. Safarinejad MR, Safarinejad S, Shafiei N, Safarinejad S. Estrogen Receptors Alpha (rs2234693 and rs9340799), and Beta (rs4986938 and rs1256049) Genes polymorphism in prostate cancer: evidence for association with risk and histopathological tumor characteristics in Iranian men. Mol Carcinog. 2012;51 Suppl 1:E104-7. CrossRef
  15. Jurecekova J, Sivonova MK, Evinova A, Kliment J, Dobrota D. The association between estrogen receptor alpha polymorphisms and the risk of prostate cancer in Slovak population. Mol Cell Biochem. 2013;381:201-. CrossRef
  16. Hernandez J, Balic I, Johnson-Pais TL, Higgins BA, Torkko KC, Thompson IM, et al. Association between an estrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men. J Urol. 2006;175:523-. CrossRef
  17. Chen YC, Kraft P, Bretsky P, Ketkar S, Hunter DJ, et al. Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2007;16:1973-1. CrossRef
  18. Modugno F, Weissfeld JL, Trump DL, Zmuda JM, Shea P, Cauley JA, et al. Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res. 2001;7:3092-.
  19. Suzuki K, Nakazato H, Matsui H, Koike H, Okugi H, Kashiwagi B, et al. Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol- / O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population. Cancer. 2003;98:1411-. CrossRef
  20. Fukatsu T, Hirokawa Y, Araki T, Hioki T, Murata T, Suzuki H, et al. Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population. Anticancer Res. 2004;24:2431-.
  21. Cunningham JM, Hebbring SJ, McDonnell SK, Cicek MS, Christensen GB, Wang L, et al. Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:969-8. CrossRef
  22. Gupta L, Thakur H, Sobti RC, Seth A, Singh SK. Role of genetic polymorphism of estrogen receptor-alpha gene and risk of prostate cancer in north Indian population. Mol Cell Biochem. 2010;335:255-1. CrossRef
  23. Sonoda T, Suzuki H, Mori M, Tsukamoto T, Yokomizo A, Naito S, et al. Polymorphisms in estrogen related genes may modify the protective effect of isoflavones against prostate cancer risk in Japanese men. Eur J Cancer Prev. 2010;19:131-. CrossRef
  24. Nicolaiew N, Cancel-Tassin G, Azzouzi AR, Grand BL, Mangin P, Cormier L, et al. Association between estrogen and androgen receptor genes and prostate cancer risk. Eur J Endocrinol. 2009;160:101-. CrossRef
  25. Sun YH, Yang B, Wang XH, Xu CL, Gao XF, Gao X, et al. Association between single-nucleotide polymorphisms in estrogen receptor beta gene and risk of prostate cancer. Chin J Surg. 2005;43:948-1.
  26. Ding X, Cui FM, Xu ST, Pu JX, Huang YH, Zhang JL. Variants on ESR1 and their association with prostate cancer risk: a meta-analysis. Asian Pac J Cancer Prev. 2012;13:3931-. CrossRef
  27. Wang YM, Liu ZW, Guo JB, Wang XF, Zhao XX, Zheng X. ESR1 Gene polymorphisms and prostate cancer risk: a HuGE review and meta-analysis. PLoS One. 2013;21:e66999. CrossRef
  28. Gu Z, Wang G, Chen W. Estrogen receptor alpha gene polymorphisms and risk of prostate cancer: a meta-analysis involving 18 studies. Tumor Biol. 2014. doi:10.1007/s13277-014-1785-4 .
  29. Hu ZY, Yu Q, Pei Q, Guo C. Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk. Clin Cancer Res. 2010;16:3832-2. CrossRef
  30. Thakkinstian A, McElduff P, D’Este C, Duffy D, Attia J. A method for meta-analysis of molecular association studies. Stat Med. 2005;24:1291-06. CrossRef
  31. Wang T, Wang B. Association between glutathione / S-transferase M1/glutathione / S-transferase T1 polymorphisms and Parkinson's disease: a meta-analysis. J Neurol Sci. 2014;338:65-0. CrossRef
  32. Zintzaras E, Ioannidis JP. HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics. 2005;21:3672-. CrossRef
  33. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-8. CrossRef
  34. Mullen B, Muellerleile P, Bryant B. Cumulative meta-analysis: a consideration of indicators of sufficiency and stability. Pers Soc Psychol Bull. 2001;27:1450-2. CrossRef
  35. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-01. CrossRef
  36. Dual S, Tweedie R. A nonparametric “trim and fill-method of accounting for publication bias in meta-analysis. J Am Stat Assoc. 2000;95:89-8.
  37. Salanti G, Amountza G, Ntzani EE, Ioannidis JP. Hardy–Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J Hum Genet. 2005;13:840-. CrossRef
  38. Bonkhoff H, Berges R. The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol. 2009;55:533-2. CrossRef
  39. Attia DM, Ederveen AG. Opposing roles of ER-alpha and ER-beta in the genesis and progression of adenocarcinoma in the rat ventral prostate. Prostate. 2012;72:1013-2. CrossRef
  40. Minelli C, Thompson JR, Abrams KR, Thakkinstian A, Attia J. The choice of a genetic model in the meta-analysis of molecular association studies. Int J Epidemiol. 2005;34:1319-8. CrossRef
  41. Ushiyama T, Ueyama H, Inoue K, Nishioka J, Ohkubo I, Hukuda S. Estrogen receptor gene polymorphism and generalized osteoarthritis. J Rheumatol. 1998;25:134-.
  42. Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, Gelernter J, et al. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet. 2003;12:205-6. CrossRef
  
• 作者单位：Chenying Fu (1)
  Wen-Qi Dong (1)
  Ani Wang (2)
  Guozhen Qiu (3)
  
  1. School of Biotechnology, Southern Medical University, Guangzhou, Guangdong, 510515, China
  2. Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, 519000, China
  3. Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510260, China
  
• ISSN：1423-0380

文摘

Estrogen receptor 1 (ESR1) and estrogen receptor 2 (ESR2) may play a role in the development of prostate cancer. Many studies focused on ESR1 rs9340799 and ESR2 rs1256049 polymorphisms to explore associations with prostate cancer risk. These studies showed inconsistent and conflicting results. The aim of this meta-analysis was to investigate the pooled association of ESR1 rs9340799 and ESR2 rs1256049 polymorphisms with prostate cancer risk. A systematic literature search was conducted to identify related studies (up to February 2014) in several online databases including PubMed, Google Scholar, CNKI and Wanfang online libraries. A total of 16 eligible articles were enrolled in this updated meta-analysis. The result suggested that ESR1 rs9340799 polymorphism was significantly associated with prostate cancer in overall populations (GG+GA vs. AA: P--.002; G vs. A: P--.004), Caucasians (GG+GA vs. AA: P--.008; G vs. A: P--.016) and Africans (GG+GA vs. AA: P--.005; G vs. A: P--.006), but not in Asians (GG+GA vs. AA: P--.462; G vs. A: P--.665). The result also showed that there was a significant association between ESR2 rs1256049 polymorphism and prostate cancer in Caucasians (AA+AG vs. GG: P--.016; A vs. G: P--.005), but no association in overall populations (AA+AG vs. GG: P--.826; A vs. G: P--.478), Asians (AA+AG vs. GG: P--.177; A vs. G: P--.703) and Africans (AA+AG vs. GG: P--.847; A vs. G: P--.707). The cumulative meta-analysis and sensitivity analysis showed the results were robust. In conclusion, this meta-analysis indicated that ESR1 rs9340799 polymorphism was associated with prostate cancer risk in overall populations, Caucasians and Africans, while ESR2 rs1256049 polymorphism was associated with prostate cancer risk in Caucasians. However, the biological mechanisms need to be further investigated.